2023 -- H 5255 | |
======== | |
LC000787 | |
======== | |
STATE OF RHODE ISLAND | |
IN GENERAL ASSEMBLY | |
JANUARY SESSION, A.D. 2023 | |
____________ | |
A N A C T | |
RELATING TO INSURANCE -- BENEFIT DETERMINATION AND UTILIZATION | |
REVIEW ACT | |
| |
Introduced By: Representatives Edwards, Ackerman, Kazarian, Alzate, Potter, Bennett, | |
Date Introduced: January 27, 2023 | |
Referred To: House Health & Human Services | |
It is enacted by the General Assembly as follows: | |
1 | SECTION 1. Chapter 27-18.9 of the General Laws entitled "Benefit Determination and |
2 | Utilization Review Act" is hereby amended by adding thereto the following section: |
3 | 27-18.9-16. Utilization review decisions. |
4 | (a) A utilization review decision shall not retrospectively deny coverage for health care |
5 | services provided to a covered person when prior approval has been obtained from the insurer or |
6 | its designee for those services, unless the approval was based upon fraudulent, materially |
7 | inaccurate, or misrepresented information submitted by the covered person, authorized person, or |
8 | the provider. |
9 | (b) For health benefit plans issued or renewed on or after the effective date of this section, |
10 | an insurer shall not require or conduct a prospective or concurrent review for a prescription |
11 | medicine: |
12 | (1) That is used in the treatment of alcohol or opioid use disorder; |
13 | (2) That contains Methadone, Buprenorphine or Naltrexone; or |
14 | (3) That was approved before the effective date of this section by the United States Food |
15 | and Drug Administration for the mitigation of opioid withdrawal symptoms. |
16 | (c) In conducting utilization reviews for Medicaid benefits, each Medicaid managed care |
17 | organization shall use the medical necessity criteria selected by the Rhode Island division of |
18 | insurance for making determinations of medical necessity and clinical appropriateness pursuant to |
| |
1 | the utilization review plan. |
2 | SECTION 2. This act shall take effect upon passage. |
======== | |
LC000787 | |
======== | |
| LC000787 - Page 2 of 3 |
EXPLANATION | |
BY THE LEGISLATIVE COUNCIL | |
OF | |
A N A C T | |
RELATING TO INSURANCE -- BENEFIT DETERMINATION AND UTILIZATION | |
REVIEW ACT | |
*** | |
1 | This act would establish a prohibition on health care insurers from requiring or conducting |
2 | a review for prescription medicine that is used in the treatment of alcohol or opioid use disorder, |
3 | that contains Methadone, Burenorphine, or Naltrexone or that was approved for the mitigation of |
4 | opioid withdrawal symptoms. |
5 | This act would take effect upon passage. |
======== | |
LC000787 | |
======== | |
| LC000787 - Page 3 of 3 |